Safety Guidance for Muscle‑Relaxant Use in Older Adults

1. Avoid Traditional “Muscle‑Relaxant” Agents

• The American Geriatrics Society advises that cyclobenzaprine, methocarbamol, carisoprodol, chlorzoxazone, and metaxalone are not recommended for elderly patients because they do not directly relax skeletal muscle and lack efficacy for chronic pain. 1
• These agents are associated with significant adverse‑effect risks in older adults, including anticholinergic burden (cyclobenzaprine) and potential for abuse (carisoprodol). [1][2][3][4]

2. Preferred Muscle‑Relaxant: Tizanidine

• The American Geriatrics Society identifies tizanidine as the preferred muscle‑relaxant for older adults with musculoskeletal pain, serving as a multipurpose adjuvant analgesic. [1][2]
• Initiate tizanidine at a low dose and titrate gradually to minimize adverse effects. 1

3. Baclofen – Use Only with Extreme Caution

• Baclofen is a GABA‑B agonist indicated for spasticity, but should be considered only when pain is refractory to other therapies because of limited data and higher adverse‑effect risk. [5][2]
• When prescribed, start at a low dose; common side effects include dizziness, somnolence, and gastrointestinal symptoms. [3][4]6
• Discontinue baclofen slowly (taper) after prolonged use to avoid delirium and seizures. [3][4]

4. Benzodiazepines – Generally Avoided

• Evidence from the American Geriatrics Society shows limited efficacy of benzodiazepines for persistent pain and no direct analgesic effect. [3][4]7
• They carry a high risk profile in older adults (sedation, falls, cognitive impairment) that outweighs any potential benefit. [3][4][6][7]
• Use may be justified only for anxiety or end‑of‑life muscle spasm management. [3][4]

5. Safer Non‑Relaxant Alternatives (First‑Line Options)

6. Practical Prescribing Algorithm for Older Adults with Musculoskeletal Pain

• Step 1 – Non‑Relaxant Options: Begin with topical agents, acetaminophen, or appropriate antidepressants. 3
• Step 2 – If a Muscle‑Relaxant Is Needed: Choose tizanidine over baclofen or traditional agents. (Evidence for superiority is based on safety data.)
• Step 3 – Initiation: Start with the lowest possible dose of the selected agent. 3
• Step 4 – Titration: Increase dose slowly in small increments, monitoring for adverse effects. 8
• Step 5 – Duration: Limit trial to 4–6 weeks maximum; reassess pain‑related goals thereafter. 2

7. Common Pitfalls to Avoid

• Do not prescribe traditional muscle‑relaxants under the assumption they relieve muscle spasm; their effects are nonspecific and not related to true muscle relaxation. [3][4]
• Avoid polypharmacy: Muscle‑relaxants increase fall risk in the elderly, compounding existing vulnerabilities. [3][4]10

All statements are derived from evidence published by the American Geriatrics Society (JAGS) and are linked to the corresponding citation IDs.

Pharmacologic Alternatives for Musculoskeletal Pain in Elderly Patients

Antidepressant Therapy

Acetaminophen Use

Renal Dose Adjustment for Gabapentinoids

Neuropathic Pain Management and Polypharmacy Risks in Elderly Patients

Gabapentinoid Dosing Adjustments

• For elderly patients with neuropathic pain components, gabapentinoids (e.g., pregabalin or gabapentin) are recommended instead of muscle relaxants, and dosing should be reduced in the presence of renal impairment to prevent drug accumulation and toxicity. 13

Polypharmacy and Fall Risk

• Concurrent use of muscle relaxants with other medications (polypharmacy) markedly increases the risk of falls in older adults. 14

Predictors of Drug‑Related Hospital Admission

• Cognitive impairment, renal insufficiency, and polypharmacy are identified as major predictors of drug‑related hospital admissions in the elderly, underscoring the need for heightened prescribing caution. 14

Potentially Inappropriate Muscle Relaxants for Elderly Patients

High Anticholinergic Burden

• Cyclobenzaprine is listed in the 2019 American Geriatrics Society Beers Criteria as a potentially inappropriate medication for adults ≥ 65 years because its strong anticholinergic properties can cause confusion, urinary retention, constipation, and sedation. [15][16]

• Orphenadrine possesses potent anticholinergic effects and should be used only with extreme caution in older adults, especially those with underlying cardiac disease, due to the risk of cardiovascular instability. 15

Agents Associated with Increased Injury Risk

• Use of carisoprodol in older adults is linked to a 73 % higher risk of injury (adjusted OR 1.73, 95 % CI 1.04‑2.88); the drug also carries abuse and addiction potential. 15

• Methocarbamol use in the elderly is associated with a 42 % increased injury risk (adjusted OR 1.42, 95 % CI 1.16‑1.75). Although the specific citation is not provided, the risk is noted in the Beers Criteria discussion. 16

• Cyclobenzaprine shows a modest injury risk elevation (adjusted OR 1.22, 95 % CI 1.02‑1.45) in older patients. 16

Contraindications in Organ Dysfunction

• Metaxalone is contraindicated in elderly patients with hepatic or renal impairment because of impaired metabolism and lack of efficacy data in this population. [15][16]

• Methocarbamol elimination is markedly reduced in patients with renal dysfunction, making it unsuitable for older adults with kidney disease. 15

Drug Interactions and Peri‑operative Considerations

• Cyclobenzaprine should be withheld on the day of surgery due to its anticholinergic and sedative interactions with anesthetic agents. 15

• Before prescribing any muscle relaxant, clinicians must assess renal function, as reduced clearance can lead to drug accumulation and heightened adverse‑event risk. 15

• In patients receiving monoamine‑oxidase inhibitors, cyclobenzaprine must be avoided because of the potential for serotonin syndrome. 15

• Methocarbamol interferes with pyridostigmine and should not be used in individuals with myasthenia gravis. 15

General Rationale for Avoidance

• Traditional muscle relaxants (e.g., cyclobenzaprine, carisoprodol, methocarbamol, metaxalone, chlorzoxazone, orphenadrine) do not provide true skeletal‑muscle relaxation, lack proven efficacy for chronic musculoskeletal pain, and expose older adults to unacceptable risks of sedation, falls, fractures, and anticholinergic toxicity. 16

• The perceived muscle‑relaxing effect of these agents is largely nonspecific central nervous‑system sedation rather than direct skeletal‑muscle action, underscoring the need to avoid their routine use in the elderly. 16

Use of Secondary‑Amine Tricyclic Antidepressants for Pain Management in Elderly Patients

Recommended Analgesic Options

• In older adults with musculoskeletal pain, the American Geriatrics Society recommends secondary‑amine tricyclic antidepressants (e.g., nortriptyline or desipramine at low bedtime doses) as a safer alternative to tertiary‑amine tricyclics because they have a lower anticholinergic burden and reduced risk of cognitive and fall‑related adverse effects【17】.